Investor Relations

AMS at a Glance

Advanced Medical Solutions Group plc is a leading developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced woundcare markets.

Our primary focus is to create quality outcomes for our:

  • Customers
  • Patients
  • Shareholders

Financial Calendar

Full Year End

31 December 2018

Half Year End

30 June 2018

Preliminary Results Announcement

March 2018
View Full Calendar

Financial Reports

2017 Interim Report

September 2017

2016 Annual Report

April 2017

2016 Interim Report

September 2016

2015 Annual Report

April 2016

2015 Interim Report

October 2015

2014 Annual Report

April 2015

2014 Interim Report

September 2014

2013 Annual Report

April 2014
View All Reports


AMS wins Medilink North West Partnership with the NHS award 2016

Advanced Medical Solutions Group plc is pleased to announce they have been awarded the Partnership with the NHS award at the Medilink North West... Read More

View More News

Latest Financial Highlights


AMS continues to perform well across the Group and is set to deliver another year of good growth and strong financial performance.

Good progress has been made with all of our brands. LiquiBand® continues to gain market share in the US, now at 24%, gaining 4% since June 2016. Our RESORBA® brands grew steadily across all territories and ActivHeal® reversed its decline and grew 9% to £3.1 million (2016 H1: £2.9 million).

We launched a number of new foam product ranges in the first half of 2016 through our OEM partners and, as previously guided, we have seen the effects of last year’s pipeline filling this year. Despite this effect, we are pleased to report that, sales in this Business Unit grew 6% at reported currency to £18.6 million (2016 H1: £17.5 million) and were unchanged at constant currency.

The Group continues to deliver a strong financial performance. Revenue increased by 17% to £45.9 million (2016 H1: £39.2 million) and by 8% at constant currency and adjusted profit before tax5 increased by 21% to £11.5 million (2016 H1: £9.5 million). Our net cash position as at 30 June 2017 was £55.2 million (31 December 2016: £51.1 million).

The Group continues to deliver solid results and is trading in line with Board expectations for the year ending 31 December 2017.